Dublin, May 08, 2018 -- The "Exosomes & Liquid Biopsies Europe 2018" conference has been added to ResearchAndMarkets.com's offering.
The Exosomes and Liquid Biopsies Europe 2018 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby circulating biomarkers of various classes are being evaluated for their potential to be developed into minimally-invasive diagnostics and liquid biopsies for cancer as well as other disease classes.
This Exosomes and Liquid Biopsies 2018 Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), protein-based circulating biomarkers, and exosomes/extracellular vesicles (EVs). There is much interest in the potential of ctDNA and EVs for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this conference bring together the most up-to-date information and current state-of-the-field.
The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for early patient monitoring.
Another component of this conference is the exploration of the science behind Exosomes and Extracellular Vesicles - Diagnostic and Therapeutic Potential.
The conference is being held in Rotterdam, The Netherlands-an excellent venue for networking with connections across The Netherlands, Europe and Worldwide. The conference includes an exhibition bringing together companies from around the world focused on developing technologies, tools, products and services serving the liquid biopsy field.
The Conference Chairman and Chief Scientific Advisor is Professor Dominique de Kleijn, Professor, University Medical Center Utrecht, The Netherlands.
Agenda:
- Circulating Tumor Cells (CTCs): Potential for Development of Liquid Biopsies
- Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
- Emerging Technologies and Emerging Companies Showcase
- Exosomes and Extracellular Vesicles (EVs): Potential for Development of Liquid Biopsies
- Exosomes as Delivery Vehicles and Therapeutic Applications of Exosomes
- Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNAs and Circulating microRNAs/Long Non-Coding RNAs
- Extracellular Vesicles (EV) in Cancer, Cardiovascular Disease, Neurological Diseases and Beyond
- Grants and Awards across the EU for Exosomes and Liquid Biopsy Research
- Regulatory Landscape for Liquid Biopsies (EU, US and Asia/Pacific)
For more information about this conference visit https://www.researchandmarkets.com/research/bscdcc/exosomes_and?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



